2563 — Beijing Biostar Pharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
- HK$1.61bn
- HK$1.61bn
- CNY66.64m
Annual income statement for Beijing Biostar Pharmaceuticals Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | HKAS | HKAS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 32.8 | 66.6 |
| Cost of Revenue | ||
| Gross Profit | 23.9 | 46.8 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Unusual Expense / Income | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 193 | 256 |
| Operating Profit | -160 | -190 |
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -161 | -190 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -161 | -190 |
| Net Income Before Extraordinary Items | ||
| Net Income | -161 | -190 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -161 | -190 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.47 | -0.56 |